Eugenia Levi, PharmD

Oruka
Kinnelon, NJ, United States

VP, Medical Affairs at Oruka Therapeutics

Presentation(s):

• 1437: Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): Oruka Therapeutics: Employee (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)